Response to lowering plasma glucose is characterised by decreased oxyntomodulin: Results from a randomised controlled trial.

Autor: Liu Y; School of Medicine, University of Auckland, Auckland, New Zealand., Kimita W; School of Medicine, University of Auckland, Auckland, New Zealand., Bharmal SH; School of Medicine, University of Auckland, Auckland, New Zealand., Petrov MS; School of Medicine, University of Auckland, Auckland, New Zealand. Electronic address: max.petrov@gmail.com.
Jazyk: angličtina
Zdroj: Diabetes & metabolic syndrome [Diabetes Metab Syndr] 2024 Jun; Vol. 18 (6), pp. 103052. Date of Electronic Publication: 2024 Jun 10.
DOI: 10.1016/j.dsx.2024.103052
Abstrakt: Background: With the prevalence of diabetes reaching an epidemic level, there is a growing interest in the investigation of its remission. Proglucagon-derived peptides (PGDP) have been shown to have a glucose-regulating effect. However, whether they play a role in diabetes remission remains poorly understood.
Aim: To investigate changes in plasma levels of PGDP in glycaemic responders versus non-responders.
Methods: The study was a randomised placebo-controlled trial comprising 18 adults with prediabetes (registered at www.
Clinicaltrials: gov as NCT03889210). Following an overnight fast, participants consumed ketone β-hydroxybutyrate (KEβHB)-supplemented beverage and placebo beverage in crossover manner. Serial blood samples were collected from baseline to 150 min at 30-min intervals. The endpoints were changes in glucagon-like peptide-1 (GLP-1), glicentin, oxyntomodulin, glucagon, and major proglucagon fragment (MPGF). Participants were stratified into the 'responders' and 'non-responders' subgroups based on their glycaemic changes following the ingestion of KEβHB. The area under the curve (AUC) was calculated to estimate the accumulated changes in the studied PGDP and compared using paired-t test between the KEβHB and placebo beverages.
Results: Responders had a significantly greater reduction in plasma glucose compared with non-responders following acute ketosis (p < 0.001). The AUC 0-150 for oxyntomodulin was significantly lower following the KEβHB beverage compared with the placebo (p = 0.045) in responders, but not in non-responders (p = 0.512). No significant differences in AUCs 0-150 were found for GLP-1, glicentin, glucagon, and MPGF in either responders or non-responders.
Conclusion: Oxyntomodulin is involved in lowering plasma glucose and may play an important role in diabetes remission.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: